Velcade and high-dose melphalan: a new preparative regimen before autologous stem cell transplantation for multiple myeloma

被引：0
|
作者：
Danho, C [1 ]
Huynh, A [1 ]
Roussel, M [1 ]
Ysebaert, L [1 ]
Recher, C [1 ]
Huguet, FR [1 ]
Nouvel, C [1 ]
Laurent, G [1 ]
Attal, M [1 ]
机构：
[1] CHU Purpan, Toulouse, France
来源：
BONE MARROW TRANSPLANTATION | 2006年 / 37卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S137 / S137
页数：1
相关论文
共 50 条
  • [31] High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.
    Rossi, Adriana C.
    Monge, Jorge
    Niesvizky, Ruben
    Hsu, Jing Mei
    Shore, Tsiporah
    Van Besien, Koen
    Pearse, Roger
    Mark, Tomer
    Jayabalan, David
    Mayer, Sebastian Alexander
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [32] Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high-dose melphalan and autologous stem cell transplantation
    Massimo Martino
    Mercedes Gori
    Gaetana Porto
    Maria Pellicano
    Ludovica Santoro
    Chiara Verduci
    Filippo Antonio Canale
    Barbara Loteta
    Tiziana Moscato
    Caterina Alati
    Maria Consuelo Ieracitano
    Amelia Cuzzocrea
    Maria Altomonte
    Maria Teresa Florenzano
    Antonella Morabito
    Giuseppe Irrera
    Virginia Naso
    Marta Pugliese
    Giuseppe Console
    Anna Ferreri
    Lucrezia Imbalzano
    Giovanni Tripepi
    Annalisa Pitino
    Annals of Hematology, 2023, 102 : 1915 - 1925
  • [33] BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
    Veeraputhiran, Muthu
    Jain, Tania
    Deol, Abhinav
    Ayash, Lois
    Kim, Seongho
    Dyson, Gregory
    Bhutani, Divaya
    Lum, Lawrence G.
    Ratanatharathorn, Voravit
    Uberti, Joseph P.
    Abidi, Muneer H.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (09): : 531 - 535
  • [34] Arsenic trioxide with ascorbic acid and high-dose melphalan for autologous hematopoietic stem cell transplantation for multiple myeloma
    Qazilbash, M. H.
    Jindani, S.
    Gul, Z.
    Saliba, R.
    Hosing, C.
    Mendoza, F.
    Qureshi, S. P.
    Weber, D. M.
    Wang, M.
    Flosser, T.
    Couriel, D. P.
    Kebriaei, P.
    Popat, U.
    Alousi, A. M.
    De Lima, M.
    Champlin, R. E.
    Giralt, S. A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (02) : 9 - 10
  • [35] Poor survival of IgD multiple myeloma following high-dose melphalan and autologous stem cell transplantation.
    Jeong, YP
    Kim, S
    Ko, OB
    Koo, JE
    Lee, D
    Suh, C
    BLOOD, 2005, 106 (11) : 373B - 373B
  • [36] Nonmyeloablative conditioning and allogeneic stem cell transplantation as consolidation therapy after high-dose melphalan and autologous stem cell transplantation for multiple myeloma
    Schneider, P
    Fenk, R
    Bernhard, A
    Huenerlituerkoglu, AN
    Aivado, M
    Wehmeier, A
    Pape, H
    Haas, R
    Kobbe, G
    BONE MARROW TRANSPLANTATION, 2002, 29 : S101 - S101
  • [37] High dose melphalan is an adequate preparative regimen for autologous hematopoietic stem cell transplantation in relapsed/refractory lymphoma
    Fernandez-Gutierrez, Jose A.
    Reyes-Cisneros, Oscar A.
    Litzow, Mark R.
    Bojalil-Alvarez, Lorena
    Garcia-Villasenor, Elizabeth
    Tomas Gomez-Gomez, Eliezer
    Murrieta-Alvarez, Ivan
    Gomez-Almaguer, David
    Gutierrez-Aguirre, Cesar H.
    Karduss-Urueta, Amado J.
    Ruiz-Delgado, Guillermo J.
    Jose Ruiz-Arguelles, Guillermo
    HEMATOLOGY, 2022, 27 (01) : 449 - 455
  • [38] High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma
    Donato, ML
    Aleman, A
    Champlin, RE
    Weber, D
    Alexanian, R
    Ippoliti, CM
    De Lima, M
    Anagnostopoulos, A
    Giralt, S
    LEUKEMIA & LYMPHOMA, 2004, 45 (04) : 755 - 759
  • [39] Busulfan, melphalan, and bortezomib compared to melphalan as a high dose regimen for autologous hematopoietic stem cell transplantation in multiple myeloma: long term follow up of a novel high dose regimen
    Hagen, Patrick
    D'Souza, Anita
    Hari, Parameswaran
    Davila, Omar
    Zhang, Mei-Jie
    Vesole, David H.
    Smith, Scott E.
    Rodriguez, Tulio E.
    Stiff, Patrick J.
    LEUKEMIA & LYMPHOMA, 2020, 61 (14) : 3484 - 3492
  • [40] Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma
    Byun, Ja Min
    Lee, Jayoun
    Shin, Sang-Jin
    Kang, Minjoo
    Yoon, Sung-Soo
    Koh, Youngil
    BLOOD RESEARCH, 2018, 53 (02) : 105 - 109
12345